A tale of two companies with a similar market cap: which to buy?
On one hand, we have an AIDS drug in Phase III trials with a global market. Lots of cash on hand.
On the other, a complementary medicine waiting for marketing approval to a virtually-bankrupt Russian health system. Virtually no cash, and are having difficulty in raising.
It's a no-brainer, really.
